breast cancer

Symposium Celebrates Award-Winning Female Scientists

Three Young Women Honored at Annual Event

Dr. Brittany Lord

There’s no doubt that science flourishes when it welcomes individuals with different backgrounds and perspectives. In pursuit of that goal, NIH has put considerable effort into closing the gender gap in the biomedical sciences, a field in which men significantly outnumber women, especially as the heads of labs and in leadership positions. Those efforts have so far yielded promising progress, with the proportion of women in IRP senior investigator positions increasing from 22 percent at the end of fiscal year 2016 to 27 percent at the end of fiscal year 2022. Over that same time period, women went from comprising 38 percent of IRP tenure-track investigators to 44 percent.

Part of what makes the IRP a welcoming place for female scientists is the NIH Women Scientists Advisors (WSA), a group of IRP scientists elected to represent the interests of women in the IRP. Once per year, the WSA selects a few female postdoctoral fellows or graduate students conducting research at NIH as WSA Scholars. At a symposium on April 13 honoring the achievements of this year’s Scholars, the awardees presented their efforts to learn more about a devastating childhood neurological condition, decrease health disparities in breast cancer, and use stem cells to investigate the roots of a nerve-destroying disorder. Read on to learn more about this year’s WSA Scholars and the important work they’re doing in their IRP labs.

Dying Tumor Cells Suppress Anti-Cancer Immune Response

IRP Study Points to Strategies to Stop Disease From Spreading

T cells (red) attacking cancer cell (white)

Ancient Greek myth describes how the hero Hercules battled the many-headed hydra, which regrew two heads every time Hercules cut one off. This frustrating fight against a seemingly invulnerable opponent would be an apt metaphor for treating cancer, in which tumor cells sometimes die in a particular way that actually helps their brethren multiply and spread to other parts of the body. In a study of that phenomenon using a mouse model of breast cancer, IRP researchers discovered that it occurs because that form of cell death suppresses the immune system’s response to the cancer, a finding that points to several potential ways to improve cancer therapy.

A Year of Honors for IRP Cancer Researchers

Four NIH Scientists Received Prestigious Recognition in 2022

clockwise from top-left: Dr. Michael Lichten, Dr. Susan Lea, Dr. Kandice Tanner, and Dr. Deborah Morrison

The complexities of cancer, which is actually a collection of many diseases, has made conquering it an enormous challenge. Fortunately, researchers in the NIH Intramural Research Program are up to the task. This year, four IRP investigators in NIH’s National Cancer Institute (NCI) have been recognized for their groundbreaking contributions to answering fundamental questions about the disease and the immune system’s response to similar threats.

IRP’s Andre Nussenzweig Elected to National Academy of Medicine

NIH Researcher Recognized for Investigation into Genomic Stability

Dr. Andre Nussenzweig

The National Academy of Medicine (NAM), first established in 1970 by the National Academy of Sciences as the Institute of Medicine (IOM), is comprised of more than 2,000 elected members from around the world who provide scientific and policy guidance on important matters relating to human health. Election to the NAM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have not only made critical scientific discoveries but have also demonstrated a laudable commitment to public service.

IRP senior investigator Andre Nussenzweig, Ph.D., was one of four IRP researchers recently elected to the NAM. Dr. Nussenzweig leads the Laboratory of Genome Integrity at the National Cancer Institute (NCI), where he studies how cells repair a form of DNA damage called a double strand break (DSB). This type of insult, which severs both strands of the double-stranded DNA molecule, is one of the most dangerous. If not repaired properly, DSBs can kill cells or cause DNA to rearrange in ways that are associated with cancer. Moreover, while DSBs can be caused by chemotherapy drugs and radiation, they can also happen by random chance during the course of normal cellular processes. Intriguingly, not all parts of the DNA molecule are equally susceptible to this form of damage.

New Treatment Creates Unwelcome Environment for Breast Cancer

Modifying Tumor’s Surroundings Stymies Cancer’s Expansion

breast cancer tumor

If you ever tried planting an apple tree in the desert or growing avocados in New England, you would quickly figure out that such plants need a particular environment in order to thrive. Cancerous tumors are no different, and IRP researchers recently found strong evidence that a molecule naturally produced in the body can suppress the growth and spread of a particularly lethal form of breast cancer via both direct effects on the cancer and by altering its surroundings.

IRP Breast Cancer Researchers Answer “Redditor” Questions

Reddit “Ask Me Anything” Commemorates Breast Cancer Awareness Month

Dr. Stanley Lipkowitz (left) and Dr. Alexandra Zimmer (right)

Breast cancer touches the lives of millions of Americans every year. In 2019 alone, researchers expect more than 300,000 American women to be diagnosed with breast cancer, along with more than 2,600 men. Roughly one out of every eight American women will develop invasive breast cancer at some point in her lifetime, making it the second most commonly diagnosed cancer in American women.

On October 9, in recognition of National Breast Cancer Awareness Month, the NIH Intramural Research Program (IRP) partnered with the National Cancer Institute (NCI) to host a Reddit “Ask Me Anything” (AMA) with two prominent researchers in the NCI's Women's Malignancies Branch: Stanley Lipkowitz, M.D., Ph.D., and Alexandra Zimmer, M.D. Between Dr. Lipkowitz’s extensive knowledge of the cellular and molecular pathways involved in breast cancer and Dr. Zimmer’s expertise in the development of clinical trials for breast cancer treatments, the pair were able to offer intriguing insights on topics ranging from recent advances in breast cancer treatment to genetic and environmental factors that influence risk for the disease. Read on for some of the most interesting exchanges that took place, or check out the full AMA on Reddit.

Breast Cancer Awareness: How the IRP Recognizes October

October is National Breast Cancer Awareness month, four weeks out of the year dedicated to bringing visibility and awareness to research in support of one of the most widespread and devastating cancers in existence.

Breast Cancer Cells